Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neither of CYP24A1 gene SNPs was associated with BC risk in the study participants.
|
31696340 |
2020 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess the associations between SNPs in the FAM13A, PHLDB1, and CYP24A1 gene and breast cancer risk in the Chinese Han population.
|
31215377 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, Cyp24a1 within MECs plays an important role in modulating postnatal and pregnancy-associated mammary gland development which provides support for inhibiting CYP24 A1 as a potential approach to activating the vitamin D pathway in breast cancer prevention and therapy.
|
30654105 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP24A1 presented a moderate diagnostic ability in breast cancer.
|
31548577 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Local alterations in the anabolism and catabolism of active vitamin D in breast cancer by the CYP27B1 and CYP24A1 may impair its anticancer functions.
|
27922682 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP24A1-induced vitamin D insufficiency promotes breast cancer growth.
|
27600601 |
2016 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer risk may be associated with specific vitamin D-related polymorphisms, particularly CYP24A1.
|
25421379 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After taking into account the false discovery rate, these SNPs were not significantly associated with breast cancer risk, nor were any of the other SNPs or haplotypes in VDR, RXRA, and CYP24A1.
|
26488576 |
2015 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues.
|
23869778 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sunlight measures were not associated with breast cancer risk, however significant interactions between time outdoors in the teen years and three unlinked genotypes were found for VDR (rs1544410, rs2228570) and CYP24A1 (rs1570669).
|
23393347 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, for rs6013897 genotypes (located at the 24-hydroxylase gene (CYP24A1)) there was a significant association with breast cancer (P<0.05).
|
22649517 |
2012 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.
|
22984610 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a case (n = 928)-control (n = 843) study of breast cancer in AA and EA women, we measured serum 25OHD levels in controls and tested associations between risk and tag single nucleotide polymorphisms (SNPs) in VDR, CYP24A1 and CYP27B1, particularly by ER status.
|
22480149 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most extensively studied SNPs including rs10735810, also known as rs2228570 (Fok1, VDR), rs1544410 (Bsm1, VDR), and rs2296241 (CYP24A1), were not associated with breast cancer risk.
|
21828234 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription.
|
20440542 |
2010 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis revealed that the CYP24 protein levels in human breast cancer were higher than in adjacent normal tissues, without an accompanying CYP24 mRNA increase.
|
19570947 |
2009 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the breast cancer tissue, the expression of 24-OHase was reduced by about 58% compared to benign tissue.
|
19667160 |
2009 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.
|
16280049 |
2005 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer.
|
14760115 |
2004 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using array CGH, amplification of 24-OHase was recently detected as a likely target oncogene of the amplification unit 20q13.2 in breast cancer cell lines and tumors.
|
15225766 |
2004 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This region contains several potential candidate genes including melanocortin 3 receptor (MC3R), cytochrome P-450 subfamily XXIV (CYP24), and breast carcinoma amplified sequence (BCAS1).
|
11242591 |
2001 |